These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 22162014)

  • 1. Optimal dose-finding designs with correlated continuous and discrete responses.
    Fedorov V; Wu Y; Zhang R
    Stat Med; 2012 Feb; 31(3):217-34. PubMed ID: 22162014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose finding designs for continuous responses and binary utility.
    Fedorov VV; Wu Y
    J Biopharm Stat; 2007; 17(6):1085-96. PubMed ID: 18027218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two-stage design for dose-finding that accounts for both efficacy and safety.
    Dragalin V; Fedorov VV; Wu Y
    Stat Med; 2008 Nov; 27(25):5156-76. PubMed ID: 18680164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toxicity-evaluation designs for phase I/II cancer immunotherapy trials.
    Messer K; Natarajan L; Ball ED; Lane TA
    Stat Med; 2010 Mar; 29(7-8):712-20. PubMed ID: 20213706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimal adaptive design in clinical drug development: a simulation example.
    Maloney A; Karlsson MO; Simonsson US
    J Clin Pharmacol; 2007 Oct; 47(10):1231-43. PubMed ID: 17906158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An adaptive dose-finding approach for correlated bivariate binary and continuous outcomes in phase I oncology trials.
    Hirakawa A
    Stat Med; 2012 Mar; 31(6):516-32. PubMed ID: 22108785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sequential designs for logistic phase I clinical trials.
    Liu G; Rosenberger WF; Haines LM
    J Biopharm Stat; 2006; 16(5):605-21. PubMed ID: 17037261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adaptive dose selection using efficacy-toxicity trade-offs: illustrations and practical considerations.
    Thall PF; Cook JD; Estey EH
    J Biopharm Stat; 2006; 16(5):623-38. PubMed ID: 17037262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple-objective designs in a dose-response experiment.
    Zhu W; Wong WK
    J Biopharm Stat; 2000 Feb; 10(1):1-14. PubMed ID: 10709797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Statistical designs for early phases of cancer clinical trials.
    Guan S
    J Biopharm Stat; 2012; 22(6):1109-26. PubMed ID: 23075011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimal designs for estimating the most successful dose.
    Zohar S; O'Quigley J
    Stat Med; 2006 Dec; 25(24):4311-20. PubMed ID: 16969893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bayesian dose-finding in phase I/II clinical trials using toxicity and efficacy odds ratios.
    Yin G; Li Y; Ji Y
    Biometrics; 2006 Sep; 62(3):777-84. PubMed ID: 16984320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose-finding design driven by efficacy in onco-hematology phase I/II trials.
    Seegers V; Chevret S; Resche-Rigon M
    Stat Med; 2011 Jun; 30(13):1574-83. PubMed ID: 21394754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An adaptive dose-finding design incorporating both toxicity and efficacy.
    Zhang W; Sargent DJ; Mandrekar S
    Stat Med; 2006 Jul; 25(14):2365-83. PubMed ID: 16220478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adaptive two-stage designs in phase II clinical trials.
    Banerjee A; Tsiatis AA
    Stat Med; 2006 Oct; 25(19):3382-95. PubMed ID: 16479547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A parallel phase I/II clinical trial design for combination therapies.
    Huang X; Biswas S; Oki Y; Issa JP; Berry DA
    Biometrics; 2007 Jun; 63(2):429-36. PubMed ID: 17688495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal and minimax three-stage designs for phase II oncology clinical trials.
    Chen K; Shan M
    Contemp Clin Trials; 2008 Jan; 29(1):32-41. PubMed ID: 17544337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exact two-stage designs for phase II activity trials with rank-based endpoints.
    Wilding GE; Shan G; Hutson AD
    Contemp Clin Trials; 2012 Mar; 33(2):332-41. PubMed ID: 22074983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimal designs for two-arm, phase II clinical trial design with multiple constraints.
    Mayo MS; Mahnken JD; Soong SJ
    J Biopharm Stat; 2010 Jan; 20(1):106-24. PubMed ID: 20077252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A hybrid Bayesian adaptive design for dose response trials.
    Chang M; Chow SC
    J Biopharm Stat; 2005; 15(4):677-91. PubMed ID: 16022172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.